Prognostic effect of programmed cell death ligand 1/programmed cell death 1 expression in cancer stem cells of human oral squamous cell carcinoma

被引:1
|
作者
Todoroki, Keita [1 ,2 ]
Abe, Yushi [1 ,2 ]
Matsuo, Katsuhisa [1 ,2 ]
Nomura, Hidetoshi [1 ]
Kawahara, Akihiko [3 ]
Nakamura, Yoshiaki [4 ]
Nakamura, Moriyoshi [1 ]
Seki, Naoko [1 ]
Kusukawa, Jingo [1 ]
机构
[1] Kurume Univ, Dent & Oral Med Ctr, Sch Med, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan
[2] Kouhoukai Med Corp, Takagi Hosp, Dept Dent & Oral Surg, Okawa, Fukuoka 8310016, Japan
[3] Kurume Univ Hosp, Dept Diagnost Pathol, Kurume, Fukuoka 8300011, Japan
[4] Oita Saiseikai Hita Hosp, Dept Dent & Oral Surg, Hita, Oita 8771292, Japan
关键词
CSC; OSCC; CD44v3; CD24; programmed cell death ligand 1; programmed cell death 1; immune checkpoint inhibitors; HEAD; PD-L1; CD24; IDENTIFICATION; IMMUNOTHERAPY; POPULATION; RECURRENT;
D O I
10.3892/ol.2024.14213
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The relationship between cancer stem cells (CSCs) in oral squamous cell carcinoma (OSCC) and programmed cell death ligand 1 (PD-L1)/programmed cell death 1 (PD-1) remains unclear. Therefore, the present study aimed to clarify the association between the CD44v3(high)/CD24(low) immunophenotype of CSCs in OSCC and PD-L1/PD-1 co-expression, and to assess the prognostic effect of CSCs in terms of immune checkpoint molecules. Formalin-fixed, paraffin-embedded tissue samples and clinicopathological data from 168 patients with OSCC were retrospectively retrieved. Immunohistochemical staining and reverse transcription quantitative polymerase chain reaction were applied to a tissue microarray of the invasive front of each case. Semi-automated cell counting was used to assess CD44v3, CD24, PD-L1 and PD-1 expression by immunohistochemistry (IHC) using a digital image analysis program. Associations between immunological markers and clinicopathological variables were estimated. Patients with the CSC immunophenotype CD44v3(high)/CD24(low), and patients with a high PD-L1/PD-1-positive cell density in the tumor parenchyma and stroma had significantly lower survival rates. Furthermore, patients with the CSC immunophenotype (CD44v3(high)/CD24(low)) and high PD-L1/PD-1 co-expression had even lower survival rates (P<0.01, log-rank test). Notably, there was a positive correlation between CD44v3 and PD-L1 expression (tau=0.1096, P=0.0366, Kendall rank correlation coefficient) and a negative correlation between CD24 and PD-1 expression (tau=-0.1387, P=0.0089, Kendall rank correlation coefficient). Additionally, the high CD44v3 expression group, as determined by IHC, exhibited significantly decreased expression of U2 small nuclear RNA auxiliary factor 1 (U2AF1) at the mRNA level compared with that in the low CD44v3 expression group (P<0.001, Mann-Whitney U test), and U2AF1 and PD-L1 mRNA expression exhibited a significant negative correlation (tau=-0.3948, P<0.001, Kendall rank correlation coefficient). In conclusion, CSCs in OSCC may evade host immune mechanisms and maintain CSC stemness via PD-L1/PD-1 co-expression, resulting in unfavorable clinical outcomes.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Programmed Cell Death Ligand 1 Expression in Osteosarcoma
    Shen, Jacson K.
    Cote, Gregory M.
    Choy, Edwin
    Yang, Pei
    Harmon, David
    Schwab, Joseph
    Nielsen, G. Petur
    Chebib, Ivan
    Ferrone, Soldano
    Wang, Xinhui
    Wang, Yangyang
    Mankin, Henry
    Hornicek, Francis J.
    Duan, Zhenfeng
    CANCER IMMUNOLOGY RESEARCH, 2014, 2 (07) : 690 - 698
  • [32] Expression of programmed cell death protein 1 and programmed cell death ligand 1 in feline injection site fibrosarcomas
    Mikiewicz, Mateusz
    Pazdzior-Czapula, Katarzyna
    Fiedorowicz, Joanna
    Otrocka-Domaga, Iwona
    RESEARCH IN VETERINARY SCIENCE, 2024, 176
  • [33] Prognostic Value of Programmed Death Ligand-1 and Human Papilloma Virus Expression in Head and Neck Squamous Cell Carcinoma
    Yeniceri, Agah
    Gonul, Ipek Isik
    Oge, Ceren Bilkan
    Duzlu, Mehmet
    ENT UPDATES, 2023, 13 (01): : 11 - 18
  • [34] Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer Reply
    Wang, Zhijie
    Zhao, Zhengyi
    Wang, Jie
    JAMA ONCOLOGY, 2020, 6 (07) : 1116 - +
  • [35] The mechanism of de novo expression of programmed cell death-ligand 1 in squamous cell carcinoma of the lung
    Igarashi, Tomoyuki
    Teramoto, Koji
    Ishida, Mitsuaki
    Hanaoka, Jun
    Daigo, Yataro
    ONCOLOGY REPORTS, 2017, 38 (04) : 2189 - 2196
  • [36] Clinical Significance of Programmed Death Ligand-1 Expression in Esophageal Squamous Cell Carcinoma
    Ito, Nozomi
    Tsujimoto, Hironori
    Horiguchi, Hiroyuki
    Shimazaki, Hideyuki
    Miyazaki, Hiromi
    Saitoh, Daizoh
    Kishi, Yoji
    Ueno, Hideki
    JOURNAL OF SURGICAL RESEARCH, 2020, 251 : 321 - 328
  • [37] Programmed Death Ligand 1 Expression in Laryngeal Squamous Cell Carcinomas and Prognosis
    Batur, Sebnem
    Kain, Zeynep Ecem
    Gozen, Emine Deniz
    Kepil, Nuray
    Aydin, Ovgu
    Comunoglu, Nil
    CLINICAL PATHOLOGY, 2020, 13
  • [38] Assessment of programmed cell death 1 and its programmed cell death ligand 1 levels in vitiligo
    Nada, Hanan R.
    Mourad, Ahmed
    Rashed, Laila A.
    El-Hanafy, Ghada M.
    Abdallah, Nermeen M. A.
    Abdelhady, Mohamed M.
    JOURNAL OF EGYPTIAN WOMENS DERMATOLOGICAL SOCIETY, 2025, 22 (01): : 79 - 87
  • [39] Tumor cell expression of programmed cell death 1 ligand 1 is a prognostic factor for malignant melanoma
    Hino, R.
    Kabashima, K.
    Kato, Y.
    Yagi, H.
    Nakamura, M.
    Honjo, T.
    Okazaki, T.
    Tokura, Y.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2009, 129 : S43 - S43
  • [40] Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials
    Huang, Zilu
    Zheng, Shuohan
    Ding, Shirong
    Wei, Yinghong
    Chen, Chen
    Liu, Xing
    Li, He
    Xia, Yunfei
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2021, 17 (03) : 676 - 687